Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Krystal Biotech (KRYS) over the last 3 years, with Q3 2025 value amounting to $17.9 million.

  • Krystal Biotech's Change in Receivables rose 40178.48% to $17.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.1 million, marking a year-over-year decrease of 6355.46%. This contributed to the annual value of $62.7 million for FY2024, which is 4915.79% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Change in Receivables is $17.9 million, which was up 40178.48% from $8.2 million recorded in Q2 2025.
  • Krystal Biotech's Change in Receivables' 5-year high stood at $56.8 million during Q2 2024, with a 5-year trough of -$5.9 million in Q3 2024.
  • For the 3-year period, Krystal Biotech's Change in Receivables averaged around $14.4 million, with its median value being $8.2 million (2025).
  • Its Change in Receivables has fluctuated over the past 5 years, first tumbled by 16375.05% in 2024, then surged by 40178.48% in 2025.
  • Quarter analysis of 3 years shows Krystal Biotech's Change in Receivables stood at $32.7 million in 2023, then plummeted by 77.24% to $7.4 million in 2024, then soared by 140.61% to $17.9 million in 2025.
  • Its last three reported values are $17.9 million in Q3 2025, $8.2 million for Q2 2025, and -$1.5 million during Q1 2025.